Abstract:Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine carcinoma of the lung that accounts for only 1% to 3% of all lung cancers and was re-classified as a distinct neuroendocrine group. There is an emerging need for an agreement on the best strategy for managing pulmonary LCNEC. Here, we reviewed our institutional experiences and tried to suggest the appropriate treatment directions for resectable pulmonary LCNEC. A total of 72 patients were pathologically diagnosed as pulmonary LCNEC between January 2005 and December 2018 in the Yonsei cancer center. We considered curative surgery first for patients with early-stage tumors or some advanced-stage tumors with resectable status, unless they were medically inoperable. Adjuvant treatment option was decided after considering each patient’s clinical and pathologic features. Consequently, 39 patients with stage I to III LCNEC (I: 18, II: 12, III: 9) underwent curative resection of the primary tumor, and these patients were included in this study cohort. In stage I, 6 (33%) patients received surgery alone, and 12 (67%) patients received adjuvant chemotherapy. In stage II, 2 (17%) patients received surgery alone and 10 (83%) patients received adjuvant chemotherapy. In stage III, only 1 (11%) patient received surgery alone, and 8 (89%) received adjuvant treatment, include 6 with adjuvant chemotherapy, 2 with sequential chemotherapy and radiotherapy (RT), and 1 with adjuvant concurrent chemoradiotherapy. With a median follow-up of 30 months, the median overall survival (OS) was 58.8 months and 3-year, 5-year rates were 58% and 47%, respectively. The median recurrence-free survival (RFS) was 24 months and 3-, and 5-year rates were 47% and 39%, respectively. In the univariate analysis for OS, older age (≥67) and SCLC-mixed histology were poor prognostic factors (p = 0.019, p = 0.001 (vs. pure LCNEC), and 0.015 (vs. NSCLC-mixed)), respectively. These 2 factors were independently associated with OS also in multivariate analysis (p = 0.036, 0.003, and 0.015). SCLC-mixed histology was the only significant factor for poor RFS. In the entire cohort, recurrences occur in 17 patients (44%). Most of the recurrence patterns were very extensive even at first recurrence; 14 distant metastases (m/c, 82%), 8 local recurrences, and 8 regional (all mediastinal lymph node) recurrences. Our study demonstrated that surgery ± adjuvant treatment could achieve favorable survival outcomes in pulmonary LCNEC. Some factors such as older age and mixed histology with SCLC made the overall prognosis worse, regardless of the stage, which proposed the need for adjuvant treatment strategies by a multidisciplinary approach. More aggressive treatments than NSCLC as mediastinal RT for node-positive patients, new chemotherapy regimens, or prophylactic cranial irradiation could be considered. Further studies in a larger cohort would be needed to draw more definitive conclusions.

Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study

Disparity in Clinical Outcomes Between Pure and Combined Pulmonary Large-Cell Neuroendocrine Carcinoma: A Multi-Center Retrospective Study.

Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma

Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung

1114P Comparative Study of Combined Large Cell Neuroendocrine Carcinoma and Combined Small Cell Carcinoma in Resected High-Grade Neuroendocrine Tumors of the Lung

Combined Large Cell Neuroendocrine Carcinoma: Clinical Characteristics, Prognosis and Postoperative Management

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis

The outcomes of different regimens depend on the molecular subtypes of pulmonary large‐cell neuroendocrine carcinoma: A retrospective study in China

The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung

Comparative Study of Large Cell Neuroendocrine Carcinoma and Small Cell Lung Carcinoma in High-Grade Neuroendocrine Tumors of the Lung: a Large Population-Based Study

Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study

Clinical Features And Outcomes Analysis Of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy

Differences between Advanced Large Cell Neuroendocrine Carcinoma and Advanced Small Cell Lung Cancer: A Propensity Score Matching Analysis

Effect of Adjuvant and Palliative Chemotherapy in Large Cell Neuroendocrine Carcinoma of the Lung: A Systematic Review and Meta-Analysis

The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma

Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage

Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer

Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas

Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

PO-1032: Clinical Features and Treatment Outcome of Resectable Pulmonary Large Cell Neuroendocrine Carcinoma